Viva Ventures in the News

At Viva Ventures, we enjoy being part of innovative teams that are helping to change the world. 

 

Please take a look at some of our partners and projects. 

Ligand.png
Cartoon.png
Cartoon.png
Liand-Complex-Sphere.png
Cartoon-Surface.png
 

Most Recent

October, 2018

EndPoints News

SQZ play: Roche doubles down on a $1.37B-plus deal for a new approach to immuno-oncology out of Bob Langer’s lab

In this new deal Roche is putting up $125 million for an upfront and near-term milestones in a collaboration deal embedded with $1 billion in development goal money. Another $250 million is on the line for each new therapy that manages to make it all the way to an approval.

Read the article

 

July, 2018

 

Viva Biotech

August, 2018

EndPoints News

Merck hands Sutro $60M to start on immunomodulatory drug discovery; Eli Lilly spinning out animal health group

China’s Viva Biotech Holdings has applied for an IPO in Hong Kong to both fund their pursuit of promising upstarts and boost their manufacturing capabilities. 

Read the article

 

August, 2018

WhaTech

Protein expression market estimated to reach US$ 1654 million by 2022

Viva Biotech is among key players operating in the protein expression market.

Read the article

 

August, 2018

EndPoints News

Summing Up: Inside the Big Drug Discovery Service Industry | Healthcare 2018

Viva Biotech is a Key Player in the Drug Discovery Service Market

Read the article

 

Our Scientific Partners*

July, 2018

Pharmaceutical Business Review

 

*This is only a small selection of recent publications